Tango Therapeutics, Inc. TNGX
22.89 USD -0.29 (-1.23%)
Nov 4, 2026, 12:04 PM EST
22.87 Day range 24.75
7.37 52-week range 34.39
- YTD
- +158.30%
- 1 year
- +185.71%
- Market cap
- 3.87B
- Revenue (ttm)
- 53.81M
- Profit margin
- -229.92%
- EPS (ttm)
- -0.85
- Shares out
- 168.61M
- Forward P/E
- -13.75
- YTD return
- +158.30%
- 1-year return
- +185.71%
- Volume
- 601.50K
- Avg volume
- 3.31M
- Open
- 24.16
- Previous close
- 23.17
- Day's range
- 22.87 – 24.75
- 52-week range
- 7.37 – 34.39
- Beta
- 1.22
- Analysts
- Strong Buy
- Price target
- 47.09 (+105.8%)
- Earnings date
- Nov 3, 2026
3M -5.64 (-19.59%)
Key statistics
- Enterprise value
- 2.69B
- PEG ratio
- 0.00
- Price / sales
- 72.60
- Price / book
- 3.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -71.87M
- Total cash
- 1.01B
- Total debt
- 31.99M
- Return on equity
- -21.34%
- Short % of float
- 26.86%
- 50-day average
- 23.56
- 200-day average
- 22.38
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.09 +105.8% upside
Now 22.89
- Target (low)
- 24.00
- Target (mean)
- 47.09
- Target (high)
- 69.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy1
- Buy11
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.35083.
Financials — quick view
TNGX Revenue — quarterly 0
TNGX Net income — quarterly -55.34M
TNGX EPS — quarterly -0.37
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.35297 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.31722 | -0.37 | -0.05 | -16.64% |
| May 13, 2026 | Mar 31, 2026 | -0.3137 | -0.32 | -0.01 | -2.01% |
| Mar 5, 2026 | Dec 31, 2025 | -0.31 | -0.29 | +0.02 | +6.45% |
| Nov 4, 2025 | Sep 30, 2025 | 0.01 | 0.13 | +0.12 | +1,200.00% |
| Aug 5, 2025 | Jun 30, 2025 | -0.35 | -0.35 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Aug 18, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 12, 2026 | Guggenheim | main | Buy | Buy |
| Jul 17, 2026 | Mizuho | main | Outperform | Outperform |
| Jul 15, 2026 | JP Morgan | init | — | Overweight |
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tangotx.com
News
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 
Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference 
Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity 
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target 
Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying 
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data 
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript 
Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings 
10 Health Care Stocks Whale Activity In Today’s Session 
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Your note
Sign in to keep a note on TNGX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRY DOUGLAS | General Counsel | Sale | Feb 4, 2025 | 66,014 |
| BECKMAN DANIELLA | Chief Financial Officer | Sale | Feb 2, 2026 | 184,297 |
| BOXER CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 5, 2024 | 0 |
| BOXER CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 5, 2024 | 0 |
| CRYSTAL ADAM S | Officer | Sale | Sep 30, 2026 | 115,743 |
| ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 6, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 8.24% | 13,900,620 | 322.08M | Jun 29, 2026 |
| Blackrock Inc. | 7.38% | 12,438,444 | 288.20M | Jun 29, 2026 |
| FMR, LLC | 7.31% | 12,333,339 | 285.76M | Jun 29, 2026 |
| Farallon Capital Management LLC | 7.28% | 12,277,000 | 284.46M | Jun 29, 2026 |
| Boxer Capital Management, LLC | 6.45% | 10,876,219 | 252.00M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 5.92% | 9,980,620 | 231.25M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.61% | 4,395,732 | 101.85M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.41% | 4,065,305 | 94.19M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.16% | 3,649,644 | 84.56M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.67% | 2,809,158 | 65.09M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.48% | 2,500,062 | 57.93M | Aug 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.92% | 1,546,027 | 35.82M | Jun 29, 2026 |